Takeda, a big Japanese drug company, has decided to stop its research on cell therapy. This is a type of treatment that uses patients’ own cells to fight diseases. The company said it will look for another company to continue this work. Takeda doesn’t have any ongoing tests of this treatment on patients right now. Instead, Takeda plans to focus on other treatments that can help patients more quickly and in a bigger way. These treatments include biologics, small molecules, and antibody drug conjugates. These are all types of medicines that can fight diseases in different ways. Takeda started working on cell therapy a few years ago, even though it was late compared to other companies. It built up its ability to make these treatments and made deals to get more treatments in development. But in the past year, Takeda has been cutting back on this work. The company is also dealing with lower profits because some of its patents have expired. As a result, it has been focusing more on treatments for autoimmune conditions, like many other companies in this field. Takeda expects to take a big financial hit, about $394 million, because of this decision. The company will also look at any other effects of this decision and include them in its next financial report, which will be released on October 30.